Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24393413 | 1.00 | MAP3K14 (0.75) | MAP3K14ADRA2AHCRTR2HTR1ACYP2D6 | |
| SCHEMBL24997240 | 1.00 | MAP3K14 (0.75) | MAP3K14ADRA2AHCRTR2HTR1ACYP2D6 | |
| SCHEMBL13505480 | 0.86 | MAP3K14 (1.00) | MAP3K14ADRA2ANPC1RAB9AAHR | |
| SCHEMBL761098 | 0.81 | MAP3K14 (0.50) | MAP3K14ADRA2AHCRTR2TERTDRD2 | |
| SCHEMBL9585265 | 0.80 | MAP3K14 (0.54) | MAP3K14ADRA2AHCRTR2TERTDRD2 | |
| SCHEMBL9585257 | 0.80 | MAP3K14 (0.54) | MAP3K14ADRA2AHCRTR2TERTDRD2 | |
| SCHEMBL9585262 | 0.80 | MAP3K14 (0.54) | MAP3K14ADRA2AHCRTR2TERTDRD2 | |
| SCHEMBL4366274 | 0.80 | MAP3K14 (0.53) | MAP3K14HTR1ACYP2D6SLC6A4DRD2 | |
| SCHEMBL1265783 | 0.79 | MAP3K14 (0.51) | MAP3K14ADRA2AHCRTR2TERTDRD2 | |
| SCHEMBL24075122 | 0.79 | MAP3K14 (0.51) | MAP3K14ADRA2AHCRTR2HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3022182-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| CN-105555766-A | Aminomethyl-biaryl derivatives as complement factor D inhibitors and uses thereof | NOVARTIS AG | 2016-05-04 | — | — | CN | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | MAP3K14 1447/4885ADRA2A 4368/4885HCRTR2 1233/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | MAP3K14 1447/4885ADRA2A 4368/4885HCRTR2 1233/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | MAP3K14 1447/4885ADRA2A 4368/4885HCRTR2 1233/4885 |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | MAP3K14 2544/4885ADRA2A 1905/4885HCRTR2 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.